Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Development of a Phototoxicity Testing Strategy for Accurate Photosafety Evaluation of Pharmaceuticals Based on the Assessment of Possible Melanin-Binding Effects.

Reinen J, van Sas P, van Huygevoort T, Rubio L, Scase K, Wenker M.

Int J Toxicol. 2018 Jul/Aug;37(4):296-307. doi: 10.1177/1091581818777998. Epub 2018 Jun 13.

PMID:
29898631
2.

Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.

Reinen J, Smit M, Wenker M.

Eur J Drug Metab Pharmacokinet. 2018 May 21. doi: 10.1007/s13318-018-0485-7. [Epub ahead of print]

PMID:
29785610
3.

Gene expression links functional networks across cortex and striatum.

Anderson KM, Krienen FM, Choi EY, Reinen JM, Yeo BTT, Holmes AJ.

Nat Commun. 2018 Apr 12;9(1):1428. doi: 10.1038/s41467-018-03811-x.

4.

The human cortex possesses a reconfigurable dynamic network architecture that is disrupted in psychosis.

Reinen JM, Chén OY, Hutchison RM, Yeo BTT, Anderson KM, Sabuncu MR, Öngür D, Roffman JL, Smoller JW, Baker JT, Holmes AJ.

Nat Commun. 2018 Mar 20;9(1):1157. doi: 10.1038/s41467-018-03462-y.

5.

Motivational Context Modulates Prediction Error Response in Schizophrenia.

Reinen JM, Van Snellenberg JX, Horga G, Abi-Dargham A, Daw ND, Shohamy D.

Schizophr Bull. 2016 Nov;42(6):1467-1475. doi: 10.1093/schbul/sbw045. Epub 2016 Apr 22.

6.

Application of a cocktail approach to screen cytochrome P450 BM3 libraries for metabolic activity and diversity.

Reinen J, Postma G, Tump C, Bloemberg T, Engel J, Vermeulen NP, Commandeur JN, Honing M.

Anal Bioanal Chem. 2016 Feb;408(5):1425-43. doi: 10.1007/s00216-015-9241-x. Epub 2016 Jan 11.

7.

Application of a Continuous-Flow Bioassay to Investigate the Organic Solvent Tolerability of Cytochrome P450 BM3 Mutants.

Reinen J, van Hemert D, Vermeulen NP, Commandeur JN.

J Biomol Screen. 2015 Dec;20(10):1246-55. doi: 10.1177/1087057115607183. Epub 2015 Sep 22.

PMID:
26396180
8.

Characterization of human cytochrome P450s involved in the bioactivation of tri-ortho-cresyl phosphate (ToCP).

Reinen J, Nematollahi L, Fidder A, Vermeulen NP, Noort D, Commandeur JN.

Chem Res Toxicol. 2015 Apr 20;28(4):711-21. doi: 10.1021/tx500490v. Epub 2015 Mar 2.

PMID:
25706813
10.

Antipsychotic dose modulates behavioral and neural responses to feedback during reinforcement learning in schizophrenia.

Insel C, Reinen J, Weber J, Wager TD, Jarskog LF, Shohamy D, Smith EE.

Cogn Affect Behav Neurosci. 2014 Mar;14(1):189-201. doi: 10.3758/s13415-014-0261-3.

PMID:
24557585
11.

Patients with schizophrenia are impaired when learning in the context of pursuing rewards.

Reinen J, Smith EE, Insel C, Kribs R, Shohamy D, Wager TD, Jarskog LF.

Schizophr Res. 2014 Jan;152(1):309-10. doi: 10.1016/j.schres.2013.11.012. Epub 2013 Dec 13. No abstract available.

PMID:
24332796
12.

Endocrine disrupting chemicals-Linking internal exposure to vitellogenin levels and ovotestis in Abramis brama from Dutch surface waters.

Reinen J, Suter MJ, Vögeli AC, Fernandez MF, Kiviranta H, Eggen RI, Vermeulen NP.

Environ Toxicol Pharmacol. 2010 Nov;30(3):209-23. doi: 10.1016/j.etap.2010.07.004. Epub 2010 Aug 3.

PMID:
21787654
13.

Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space.

Reinen J, van Leeuwen JS, Li Y, Sun L, Grootenhuis PD, Decker CJ, Saunders J, Vermeulen NP, Commandeur JN.

Drug Metab Dispos. 2011 Sep;39(9):1568-76. doi: 10.1124/dmd.111.039461. Epub 2011 Jun 14.

14.

Application of a fluorescence-based continuous-flow bioassay to screen for diversity of cytochrome P450 BM3 mutant libraries.

Reinen J, Ferman S, Vottero E, Vermeulen NP, Commandeur JN.

J Biomol Screen. 2011 Feb;16(2):239-50. doi: 10.1177/1087057110394180.

PMID:
21297109
15.

Application of cytochrome P450 BM3 mutants as biocatalysts for the profiling of estrogen receptor binding metabolites of the mycotoxin zearalenone.

Reinen J, Kalma LL, Begheijn S, Heus F, Commandeur JN, Vermeulen NP.

Xenobiotica. 2011 Jan;41(1):59-70. doi: 10.3109/00498254.2010.525762. Epub 2010 Nov 18.

PMID:
21087115
16.

Health-related quality of life and survival in liver transplant candidates.

Tanikella R, Kawut SM, Brown RS Jr, Krowka MJ, Reinen J, Dinasarapu CR, Trotter JF, Roberts KE, Mohd MA, Arnett DK, Fallon MB.

Liver Transpl. 2010 Feb;16(2):238-45. doi: 10.1002/lt.21984.

17.

Comparison of murine and human estrogen sulfotransferase inhibition in vitro and in silico--implications for differences in activity, subunit dimerization and substrate inhibition.

Stjernschantz E, Reinen J, Meinl W, George BJ, Glatt H, Vermeulen NP, Oostenbrink C.

Mol Cell Endocrinol. 2010 Apr 12;317(1-2):127-40. doi: 10.1016/j.mce.2009.12.001. Epub 2009 Dec 16.

PMID:
20025931
18.

Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation.

Rybak D, Fallon MB, Krowka MJ, Brown RS Jr, Reinen J, Stadheim L, Faulk D, Nielsen C, Al-Naamani N, Roberts K, Zacks S, Perry T, Trotter J, Kawut SM; Pulmonary Vascular Complications of Liver Disease Study Group.

Liver Transpl. 2008 Sep;14(9):1357-65. doi: 10.1002/lt.21545.

19.

Reversed-phase liquid chromatography coupled on-line to estrogen receptor bioaffinity detection based on fluorescence polarization.

Reinen J, Kool J, Vermeulen NP.

Anal Bioanal Chem. 2008 Apr;390(8):1987-98. doi: 10.1007/s00216-008-1833-2. Epub 2008 Jan 31.

20.

Development and validation of a fluorescence HPLC-based screening assay for inhibition of human estrogen sulfotransferase.

Reinen J, Vriese E, Glatt H, Vermeulen NP.

Anal Biochem. 2006 Oct 1;357(1):85-92. Epub 2006 Aug 1.

PMID:
16914110
21.

Development and validation of a microsomal online cytochrome P450 bioreactor coupled to solid-phase extraction and reversed-phase liquid chromatography.

van Liempd SM, Kool J, Reinen J, Schenk T, Meerman JH, Irth H, Vermeulen NP.

J Chromatogr A. 2005 May 20;1075(1-2):205-12.

PMID:
15974134

Supplemental Content

Loading ...
Support Center